An international panel has updated its guidelines for chimeric antigen receptor (CAR) T-cell therapy in people with ...

Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.

A pharmacovigilance analysis of nearly five million adverse-event reports finds that liver injury after CAR T-cell therapy is ...

Cancer-fighting T cells can lose their edge after prolonged exposure to tumors. New research from Memorial Sloan Kettering ...

An international multidisciplinary group of 31 experts has updated consensus recommendations to guide the use of CAR T-cell ...

Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and ...

Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer ...

Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing ...

A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Abogen Biosciences has entered into a licensing and option agreement with Novartis covering ABO2203 and additional potential ...